<div id="readability-page-1"><div><ul> <li>In recent weeks, Morgan Stanley reported a first-quarter 2026 earnings beat driven by strong advisory revenues, robust trading performance, and record results in its Institutional Securities and Wealth Management divisions, while also declaring regular dividends across eleven preferred stock series payable in June and July 2026.</li> <li>At the same time, the firm has taken a visibly optimistic stance on U.S. equities and AI-driven earnings trends, underlining management’s confidence in its core businesses and the broader market backdrop supporting its wealth and investment banking franchises.</li> <li>With this backdrop of an earnings beat and upbeat market outlook, we’ll now examine how these developments reshape Morgan Stanley’s investment narrative.</li> </ul><p>Find 51 companies with promising cash flow potential yet trading below their fair value.</p><h2>Morgan Stanley Investment Narrative Recap</h2><p>To own Morgan Stanley, you have to believe its mix of institutional securities and wealth management can keep generating solid earnings and capital returns despite fee pressure, regulation, and fintech competition. The latest earnings beat reinforces that short term, the key catalyst remains execution in advisory and trading, while the biggest risk is long term margin pressure from shifts toward low fee passive products. The preferred dividend news does not materially change that risk reward balance.</p> <p>The most relevant development here is the regular preferred dividend declaration across eleven series, alongside earlier common dividends and ongoing buybacks. Together, these moves highlight that Morgan Stanley is still allocating substantial cash to investors even as it ramps up AI initiatives and expands market access through platforms like LTX and Abu Dhabi Securities Exchange. For shareholders focused on capital return as a near term catalyst, this consistency is an important data point.</p> <p>But against this relatively upbeat picture, investors should also be aware that a sharp acceleration in passive investing and fee compression could...</p> <p>Read the full narrative on Morgan Stanley (it's free!)</p><p>Morgan Stanley's narrative projects $83.2 billion revenue and $19.7 billion earnings by 2029. This requires 5.8% yearly revenue growth and a $3.5 billion earnings increase from $16.2 billion.</p><p>Uncover how Morgan Stanley's forecasts yield a $190.33 fair value, in line with its current price.</p><h2>Exploring Other Perspectives</h2><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0d015bad-cbbd-4193-825d-b6c6f88a429f/chart/quote-price?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0d015bad-cbbd-4193-825d-b6c6f88a429f/chart/quote-price"/><figcaption>MS 1-Year Stock Price Chart</figcaption></figure> <p>While recent results look strong, the most pessimistic analysts were previously assuming revenue of about US$79.7 billion and earnings of roughly US$17.4 billion by 2029, which reflects a much tougher view than the consensus and shows how differently you and other investors might see the same Morgan Stanley headlines.</p><p>Explore 4 other fair value estimates on Morgan Stanley - why the stock might be worth as much as 15% more than the current price!</p><h2>The Verdict Is Yours</h2><p>Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.</p><ul><li>A great starting point for your Morgan Stanley research is our analysis highlighting 4 key rewards and 3 important warning signs that could impact your investment decision.</li><li>Our free Morgan Stanley research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Morgan Stanley's overall financial health at a glance.</li></ul><h2>No Opportunity In Morgan Stanley?</h2><p>Our daily scans reveal stocks with breakout potential. Don't miss this chance:</p><ul><li>AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.</li><li>Uncover the next big thing with 27 elite penny stocks that balance risk and reward.</li><li>The latest GPUs need a type of rare earth metal called Neodymium and there are only 30 companies in the world exploring or producing it. Find the list for free.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>• Connect an unlimited number of Portfolios and see your total in one currency<br/>• Be alerted to new Warning Signs or Risks via email or mobile<br/>• Track the Fair Value of your stocks<br/></p><p>Try a Demo Portfolio for Free</p></div></div></div>

PEPS

CVLC

<p>Morgan Stanley reported a strong Q1 2026 earnings beat, driven by advisory revenues and trading performance, while maintaining regular dividends across eleven preferred stock series. The firm is optimistic about U.S. equities and AI-driven earnings trends, projecting $83.2 billion in revenue and $19.7 billion in earnings by 2029. Despite potential long-term risks from fee compression, the consistent capital return to shareholders remains a key focus. Analysts have varying views on the stock's fair value, with some suggesting it could be worth 15% more than its current price.</p>

Simplywall

Morgan Stanley

Parametric Equity Plus ETF

Calvert US Large-Cap Core Responsible Index ETF

Calvert US Large-Cap Diversity Equity & Inclusion Index ETF

Fidelity MSCI Financials Index

Eaton Vance Intermediate Municipal Income ETF

Financial Select Sector SPDR Fund

Calvert Ultra-Short Investment Grade ETF

VG Financial

Eaton Vance Ultra-Short Income ETF

Calvert US Mid-Cap Core Responsible Index ETF

Parametric Hedged Equity ETF

Parametric Equity Premium Income ETF

Morgan Stanley Pathway Sm-Md Cp Eq ETF

Eaton Vance High Yield ETF

Calvert International Responsible Index ETF

ISHRS Us Brokers & Sec Exchg

Calvert US Select Equity ETF

Morgan Stanley Pathway Large Cap Eq ETF

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

How Investors Are Reacting To Morgan Stanley (MS) Earnings Beat And Optimistic AI-Driven Outlook